Company intelligence / Profile preview

Femtogenix

Harpenden, Hertfordshire, United Kingdom

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Femtogenix develops DNA-interactive payloads (pyridinobenzodiazepine mono‑alkylators such as FGX20‑75 and FGX2‑62) for antibody-drug conjugates; published data show high in vitro potency, strong in vivo efficacy and improved tolerability in xenograft models, but there are no disclosed clinical-stage assets yet.[2][4][7]

Therapeutic areas: OncologyHematology
Modalities: Antibody-drug conjugateSmall molecule
Industry: Biotech

Drug pipeline

2 assets

FGX2-62

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Iksuda Therapeutics (use of Femtogenix FGX2‑62 payload in IKS-01 ADC)[4]

Beyond the preview

Go deeper on Femtogenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Femtogenix.

Explore the full profile